177 related articles for article (PubMed ID: 27741010)
21. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
22. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
Kim SJ; Koo PJ; Chang S
Cancer Chemother Pharmacol; 2016 Apr; 77(4):723-31. PubMed ID: 26891957
[TBL] [Abstract][Full Text] [Related]
24. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
[TBL] [Abstract][Full Text] [Related]
25. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer.
Vollenbrock SE; Voncken FEM; van Dieren JM; Lambregts DMJ; Maas M; Meijer GJ; Goense L; Mook S; Hartemink KJ; Snaebjornsson P; Ter Beek LC; Verheij M; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Br J Surg; 2019 Apr; 106(5):596-605. PubMed ID: 30802305
[TBL] [Abstract][Full Text] [Related]
27. Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.
Voncken FEM; Aleman BMP; van Dieren JM; Grootscholten C; Lalezari F; van Sandick JW; Steinberg JD; Vegt E
Strahlenther Onkol; 2018 Feb; 194(2):156-163. PubMed ID: 29051991
[TBL] [Abstract][Full Text] [Related]
28. Complete metabolic response is not uniformly predictive of complete pathologic response after induction therapy for esophageal cancer.
Stiles BM; Salzler G; Jorgensen A; Nasar A; Paul S; Lee PC; Port JL; Altorki NK
Ann Thorac Surg; 2013 Nov; 96(5):1820-5. PubMed ID: 23895888
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of
Valkema MJ; Noordman BJ; Wijnhoven BPL; Spaander MCW; Biermann K; Lagarde SM; Bennink RJ; Schreurs WMJ; Roef MJ; Hobbelink MGG; Janssen MJR; Graven LH; van Lanschot JJB; Valkema R
J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
[TBL] [Abstract][Full Text] [Related]
30. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
31. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.
van der Wilk BJ; Eyck BM; Doukas M; Spaander MCW; Schoon EJ; Krishnadath KK; Oostenbrug LE; Lagarde SM; Wijnhoven BPL; Looijenga LHJ; Biermann K; van Lanschot JJB
Br J Surg; 2020 Dec; 107(13):1791-1800. PubMed ID: 32757307
[TBL] [Abstract][Full Text] [Related]
32. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer.
Giovannini M; Seitz JF; Thomas P; Hannoun-Levy JM; Perrier H; Resbeut M; Delpero JR; Fuentes P
Endoscopy; 1997 Jan; 29(1):4-9. PubMed ID: 9083729
[TBL] [Abstract][Full Text] [Related]
33. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
[TBL] [Abstract][Full Text] [Related]
34. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
35. Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus.
Dewan A; Sharma SK; Dewan AK; Khurana R; Gupta M; Pahuja A; Srivastava H; Sinha R
J Gastrointest Cancer; 2017 Mar; 48(1):42-49. PubMed ID: 27604122
[TBL] [Abstract][Full Text] [Related]
36. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
38. Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation.
Lee J; Choi JY; Lim SW; Ahn MJ; Park K; Zo JI; Shim YM; Oh D; Sun JM
Eur J Cardiothorac Surg; 2020 Nov; 58(5):1019-1026. PubMed ID: 32920638
[TBL] [Abstract][Full Text] [Related]
39. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
